(Q37788981)

23 August 2017

Examining the safety profile of angiogenesis inhibitors: implications for clinical practice (English)

1 reference

23 August 2017

angiogenesis inhibitor

1 reference

Martin Reck

1

1 reference

23 August 2017

15 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

5

1 reference

23 August 2017

257-267

1 reference

23 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-010-0159-0

23 August 2017

0 references

cites work

Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0159-0

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0159-0

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

12 December 2020

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

12 December 2020

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

1 reference

12 December 2020

Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?

1 reference

12 December 2020

Incidence and pathogenesis of thrombosis in hematologic malignancies

1 reference

12 December 2020

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

1 reference

12 December 2020

Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions

1 reference

12 December 2020

Abnormal pressure-natriuresis in hypertension: role of nitric oxide

1 reference

12 December 2020

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Role of vascular endothelial growth factor in the regulation of angiogenesis

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

12 December 2020

Vascular endothelial growth factor trap in non small cell lung cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Sunitinib: from rational design to clinical efficacy

1 reference

12 December 2020

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer

1 reference

12 December 2020

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

12 December 2020

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

12 December 2020

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

1 reference

12 December 2020

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

12 December 2020

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments

1 reference

12 December 2020

Role of platelet-derived growth factors in physiology and medicine

1 reference

12 December 2020

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

12 December 2020

Sorafenib for metastatic renal cancer: the Princess Margaret experience

1 reference

12 December 2020

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

1 reference

12 December 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

12 December 2020

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

12 December 2020

Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway

1 reference

12 December 2020

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S11523-010-0159-0

Identifiers

DOI

1 reference

release_koxkprx44zgpnbsuictnf6bm2y

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/koxkprx44zgpnbsuictnf6bm2y

24 November 2022

mapped directly with Wikidata item

PubMed ID

20842461

1 reference

PubMed ID

20842461